

MedNess newsletter November 21, 2023

From MedNess <newsletter@medness.org>

Para sarah@medness.org

Fecha martes, 21 de noviembre de 2023 a las 19:05

[Click here if this email doesn't show properly](#)



MedNess **(Onco-This-Week)**

bite-size biopharma and medtech news

November 21, 2023


MedNess News Highlights this week



Exact Sciences

Exact Sciences was founded in 1995 with the visionary, and perhaps ahead of its time goal of developing non-invasive colorectal cancer (CRC) testing. The company's early and innovative stool-DNA tests...

[Read the post](#)



Aquinnah's potential Alzheimer's drug capable of reducing ~70% brain tau pathology

Aquinnah Pharmaceuticals recently announced the preclinical findings on its novel therapeutic designed to slow or stop the progression of Alzheimer's Disease (AD) and related disorders. Their drug discovery relies on identifying...

[Read the post](#)



CONFERENCE COVERAGE: 2023 SITC Annual Meeting

Candel Therapeutics Announces Initial Positive Interim Data from Randomized Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer Coherus Presents Data from Next-generation Immuno-oncology Programs Cullinan Oncology to Present...

[Read the post](#)



Karyopharm Announces Clinical Trial Collaboration with BMS to Evaluate CELMoD Agent CC- 92480 Mezigdomide + Selinexor in Patients with R/R Multiple Myeloma

"This is an important collaboration with Bristol Myers Squibb to explore this novel and entirely oral combination in patients who have progressed following T-cell engaging therapy. This trial will also...

[Read the post](#)



Prelude Therapeutics and AbCellera Enter Partnership to Develop First-in-Class Precision ADCs in Oncology

“We made significant progress in the third quarter with our four clinical stage molecules and, as planned, conducted a rigorous assessment of each program. Based on this assessment, we are...

[Read the post](#)



Disclaimer

The editors take care to share authentic information. In case of any discrepancies please write to newsletter@medness.org

The sponsors do not have any influence on the nature or kind of the news/analysis reported in MedNess. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of MedNess. Examples of analysis performed within this article are only examples. They should not be utilized in real-world analytic products as they are based only on very limited and dated open source information. Assumptions made within the analysis are not reflective of the position of anyone volunteering or working for MedNess. This blog is strictly for news and information. It does not provide medical advice, diagnosis or treatment nor investment suggestions. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or another qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.

MedNess is a part of STEMPeers® which is a 501(c)(3) organization registered in PA as PhD Career Support Group. The organization helps create a growing network of STEM scientists that is involved in peer to peer mentoring and support.

You're receiving this email because you subscribed to it at MedNess as sarah@medness.org.

To modify or cancel your subscription, [click here](#).

